摘要
高级别胶质瘤是最常见且恶性程度最高的中枢神经系统恶性肿瘤,复发后的侵袭性更强,常规放化疗的疗效不佳。贝伐单抗是批准用于治疗复发性胶质瘤的一种抗血管内皮生长因子单克隆抗体。近年来,开展了许多有关贝伐单抗联合其他治疗手段治疗复发性高级别胶质瘤的临床研究,但对于联合用药的疗效、模式及安全性尚存有较多争议。本文对贝伐单抗应用于复发性高级别胶质瘤治疗的最新进展进行综述,以期为临床上使用贝伐单抗治疗复发性高级别胶质瘤提供参考。
High-grade glioma（HGG） is the most primary and malignancy brain tumor in central nervous system.Its invasiveness is often increased after recurrence and it has a poor response to chemoradiotherapy.Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor（VECF）,which was approved by Food and Drug Administration（FDA） for the treatment of recurrent glioma.In recent years,the clinical research on bevacizumab combined with other therapeutic approaches in treating recurrent HCC is ongoing.However,there are still some disputes in effectiveness of treatment,treatment modalities and safety of combined drug regimen.In this paper,the related studies about bevacizumab in treating recurrent HCC are summarized,for purpose of enhancing the understanding of its current clinical application and exploring its future research direction.
出处
《肿瘤》
CAS
CSCD
北大核心
2016年第7期814-818,共5页
Tumor
基金
国家自然科学基金面上项目(编号:81472812)~~
